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Abstract
AIM: To understand the factors associated with negative conversion of severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) RNA, targeted surveillance and control measures can be taken to provide scientific 
basis for the treatment of the disease and to improve the prognosis of the disease.
METHODS: Using the method of retrospective cohort study, we collected the data of Coronavirus Disease 2019 
(COVID-19) patients in Tongji Hospital of Wuhan, China from 10 January to 25 March, 2020. Among the data of 282 
cases, 271 patients, according to whether the negative conversion happened, were divided into negative conversion 
group and control group. We made the quantitative variables into classification; Chi-square test single-factor and 
Cox regression were used in univariate analysis and extracted 30 meaningful variables, then through the collinearity 
diagnosis, excluded the existence of collinear variables. Finally, 22 variables were included in Cox regression analysis.
RESULTS: The gender distribution was statistically significant between two groups (p < 0.05). While in the negative 
conversion group, the patients of non-severe group occupied a large proportion (p < 0.001). The median time for the 
negative conversion group was 17 days, and at the end of the observation period, the virus duration in control group 
was 24 days (p < 0.05). A total of 55 variables were included in univariate analysis, among which 30 variables were 
statistically different between the two groups. After screening variables through collinearity diagnosis, 22 variables 
were included in the Cox regression analysis. Last, lactate dehydrogenase (LDH), age, fibrinogen (FIB), and disease 
severity were associated with negative conversion of SARS-CoV-2 RNA.
CONCLUSION: Our results suggest that in the treatment of COVID-19, focus on the age of more than 65 years 
old, severe, high level of LDH, FIB patients, and take some targeted treatment, such as controlling of inflammation, 
reducing organ damage, so as to provide good conditions for virus clearance in the body.
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Introduction
At present, the coronavirus disease (COVID)-
19 has been a global outbreak, which was first reported 
in Wuhan, the capital of Hubei, China. A novel CoV, 
named severe acute respiratory syndrome CoV 2 
(SARS-CoV-2) was isolated and it is the seventh member 
of the family of CoVs that infect humans [1]. It is so 
highly contagious that most individuals are susceptible 
to infection. As for main sources, the wild animals and 
infected patients are of infectiousness [2]. COVID-19 
has been spread to 216 countries, areas or territories 
[3]. According to the latest statistics of the World Health 
Organization, as of July 26, 2020, more than 15,785,641 
cases of the disease have been confirmed with over 
640,016 deaths, making COVID-19 a major health 
concern [4]. Current research on COVID-19 focuses on 
the epidemics, its clinical features, and treatment [5]. 
In this case, study the factors associated with negative 
conversion of viral RNA is of necessary to guide the 
isolation precautions and antiviral treatment.
This study aims to assess the risk factors 
associated with prolonged viral shedding to improve 
treatment and prognosis of COVID-19 by considering 
or adjusting relative factors.
Materials and Methods
Study design and data collection
This retrospective cohort study contains a 
total of 282 laboratory-confirmed COVID-19 patients 
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who were admitted to Tongji Hospital of Wuhan, 
China from 10 January to 25 March, 2020. All patients 
were collected throat swab samples and SARS-
CoV-2 RNA was detected using real-time reverse 
transcription polymerase chain reaction. Data of 
demographic characteristics, comorbidities, symptoms, 
and laboratory values were collected using electronic 
medical records. A total of 271 patients were included 
in the study, excluding 11 cases whose results changed 
repeatedly and cannot judge the time of negative 
conversion. Ethical Committee of Tongji Hospital of 
Huazhong University of Science and Technology (No.
TJ-IRB20200364) and China-Japan Union Hospital of 
Jilin University (No.2020032607) approved the study 
and waived the written informed consent for rapid 
emerging infectious.
Definitions of basic concepts
To minimize the uncertainty of nucleic acid test, 
the time when a viral nucleic acid test was negative 
was defined as the time from the first onset of related 
symptoms to the time when two consecutive nucleic 
acid tests results were negative before discharge from 
the hospital, while for cases with the absence of the time 
of first symptom, the time of admission was replaced. 
If both were missing, the first sampling time was used 
instead. In the case of death, the time interval between 
the onset of symptoms and discharge was calculated 
without nucleic acid test data and was classified as 
non-negative group. Patients who returned to positive 
nucleic acid test after discharge and patients who were 
impossible to judge the time of negative conversion 
were excluded from the study.
General conditions and laboratory test 
indicators
We collected the patient’s name, gender, 
disease severity, first symptom, basic diseases, urine 
routine, blood routine, erythrocyte sedimentation rate, 
glucose, biochemistry, coagulation, cytokines, and other 
indicators for the first admission test. Indicators with a 
missing value greater than 20% were not included in 
the analysis.
Statistical analysis
First, the indicators included in the analysis 
were analyzed by single factor analysis. According to 
the reference range of normal values, the quantitative 
variables were set as dichotomy or multiple 
categorization variables. Chi-square test and single-
factor Cox regression were used to compare the negative 
conversion group and the control group. The test level 
was 0.05. To reduce the influence of the inclusion of 
variables on the stability of the model, the missing value 
of variables was filled, and the mean value method was 
used to fill. Then, the variables whose p values in the 
two single-factor test methods were both <0.05 were 
included in multivariate Cox regression analysis. The 
analysis software was IBM SPSS Statistics Version 
24.0 and GraphPad Prism Version 8.2.1.
Results
The basic situation
It can be seen that the gender distribution was 
statistically significant between two groups (p < 0.05), 
while in the negative conversion group, the patients 
of non-severe disease occupied a large proportion 
(78.4%, p < 0.001). The median time for the negative 
conversion group was 17 days, and at the end of the 
observation period, the virus duration was 24 days (p 
< 0.05). The proportion of those older than 65 in the 
control group was larger (p < 0.05), as shown in Table 1.
Single factor analysis
Univariate analysis was performed for 
variables that were filled in missing values and 
converted into categorizing variables. A total of 55 
variables were included, among which 30 variables 
were statistically different between the two groups, as 
shown in Table 1.
Then, to avoid collinearity among independent 
variables, which would affect the multi-factor analysis, 
collinearity diagnostics was made for quantitative 
variables with statistical significance, and the results 
are shown in Table 2.
As shown in Table 2, the VIF of calcium ion, 
HCO, interleukin (IL)-6, PCT, AST, and IL-8 were 
nearly or more than 10, which indicated the existence 
of collinearity. Since IL-6 and 8 had been widely 
reported in the previous studies [6], [7], [8], [9], [10], 
[11], [12], cytokine IL-10 was retained in this study to 
explore the influence of cytokine IL-10 on the negative 
transformation of COVID-19 virus. In addition, because 
we had enough variables, we deleted these variables 
as appropriate. After that, some variables were deleted 
because their VIF >4 and there were still variables of 
the same type. They were BU and eGFR.
After adjustment, there was no obvious 
collinearity between variables (Table 3). Although the 
VIF of TP is 3.132, we incorporated it into the analysis 
not to delete important variable. The screened 
variables were incorporated into Cox regression 
model for analysis. The analysis results were shown 
in Table 4.
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Table 1: Results of single factor analysis
Variables Group (%) χ2 p-value
Control (n = 49) Negative conversion (n = 222)
Disease severity
Non-severe 2 (4.1) 174 (78.4) 97.324 <0.001
Severe 47 (95.9) 48 (21.6)
UPRO
N 2 (4.1) 108 (48.6) 33.062 <0.001
P 47 (95.9) 114 (51.4)
Gender
Male 33 (67.3) 112 (50.5) 4.607 0.032
Female 16 (32.7) 110 (49.5)
U-KET
N 32 (65.3) 198 (89.2) 17.831 <0.001
P 17 (34.7) 24 (10.8)
URO
N 43 (87.8) 216 (97.3) 6.529 0.011
P 6 (12.2) 6 (2.7)
WBC
Normal 17 (34.7) 177 (79.7) 48.619 <0.001
Low 2 (4.1) 12 (5.4)
High 30 (61.2) 33 (14.9)
NEUT
Normal 11 (22.4) 167 (75.2) 58.102 <0.001
Low 1 (2.0) 10 (4.5)
High 37 (75.5) 45 (20.3)
LC
Normal 3 (6.1) 109 (49.1) 30.575 <0.001
Abnormal 46 (93.9) 113 (50.9)
NT-PROBNP
Normal 8 (16.3) 114 (51.4) 19.894 <0.001
High 41 (83.7) 108 (48.6)
PCT
Normal 1 (2.0) 91 (41.0) 27.158 <0.001
High 48 (98.0) 131 (59.0)
Hypersensitive cardiac troponin
Normal 17 (34.7) 170 (76.6) 32.921 <0.001
High 32 (65.3) 52 (23.4)
AST
Normal 16 (32.7) 162 (73.0) 28.950 <0.001
High 33 (67.3) 60 (27.0)
TP
Normal 24 (49.0) 183 (82.4) 24.902 <0.001
Abnormal 25 (51.0) 39 (17.6)
Albumin
Normal 7 (14.3) 105 (47.3) 18.040 <0.001
Low 42 (85.7) 117 (52.7)
DBIL
Normal 30 (61.2) 200 (90.1) 26.048 <0.001
Abnormal 19 (38.8) 22 (9.9)
GGT
Normal 30 (61.2) 172 (77.5) 5.587 0.018
Abnormal 19 (38.8) 50 (22.5)
LDH
Normal 0 (0.0) 60 (27.0) 17.009 <0.001
Abnormal 49 (100.0) 162 (73.0)
Sodium
Normal 26 (53.1) 183 (82.4) 29.732 <0.001
Low 9 (18.4) 28 (12.6)
High 14 (28.6) 11 (5.0)
Calcium ion
Normal 7 (14.3) 95 (42.8) 13.898 <0.001
Abnormal 42 (85.7) 127 (57.2)
BU
Normal 24 (49.0) 145 (65.3) 41.100 <0.001
Low 1 (2.0) 51 (23.0)
High 24 (49.0) 26 (11.7)
HCO
Normal 18 (36.7) 176 (79.3) 53.127 <0.001
Low 30 (61.2) 30 (13.5)
High 1 (2.0) 16 (7.2)
eGFR
Normal 11 (22.4) 104 (46.8) 9.781 0.002
Abnormal 38 (77.6) 118 (53.2)
PT
Normal 12 (24.5) 170 (76.6) 49.376 <0.001
Abnormal 37 (75.5) 52 (23.4)
INR
Normal 24 (49.0) 194 (87.4) 37.638 <0.001
Abnormal 25 (51.0) 28 (12.6)
Age (year)
≤65 13 (26.5) 110 (49.5) 8.581 0.003
>65 36 (73.5) 112 (50.5)
FIB
Normal 18 (36.7) 67 (30.2) 14.199 0.001
Low 6 (12.2) 4 (1.8)
High 25 (51.0) 151 (68.0)
D-D dimer quantification
Normal 1 (2.0) 59 (26.6) 14.018 <0.001
Abnormal 48 (98.0) 163 (73.4)
(Contd...)
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Variables Group (%) χ2 p-value
Control (n = 49) Negative conversion (n = 222)
IL-2R
Normal 4 (8.2) 111 (50.0) 35.554 <0.001
Low 1 (2.0) 16 (7.2)
High 44 (89.8) 95 (42.8)
IL-6
Normal 2 (4.1) 106 (47.7) 31.930 <0.001
Abnormal 47 (95.9) 116 (52.3)
IL-8
Normal 35 (71.4) 216 (97.3) 35.604 <0.001
Abnormal 14 (28.6) 6 (2.7)
IL-10
Normal 19 (38.8) 177 (79.7) 33.636 <0.001
Abnormal 30 (61.2) 45 (20.3)
UPRO: Urine protein; P: positive; N: Negative; U-KET: urine ket; URO: Urobilinogen; WBC: white blood cell count (normal: 3.50–9.50 low: <3.50 high: >9.50, 109/L); NEUT: neutrophil count (normal: 1.80–6.30 low: <1.80 high: 
>6.30, 109/L); LC: lymphocyte count (normal: 1.10–3.20 abnormal: <1.10 or >3.20,109/L); NT-PROBNP: amino-terminal pro-brain natriuretic peptide (normal: <241/285 (male/female) high: ≥241/285 (male/female), pg/mL); 
PCT: Procalcitonin (normal: 0.02–0.05 high: ≥0.05, ng/mL); Hypersensitive cardiac troponin (normal: ≤34.2/15.6 (male/female) high: >34.2/15.6 (male/female), pg/mL); AST: Glutamic oxalacetic transaminase (normal: ≤40/32 
(male/female) high: >40/32 (male/female) U/L); TP: Total protein (normal: 64–83 abnormal: <64 or >83, g/L); Albumin (normal: 35–52 low: <35, g/L); DBIL: Direct bilirubin (normal: ≤8.0 abnormal: >8.0, μmol/L); GGT: Gamma-
glutamyl transpeptidase (normal: 10/6–71/42 (male/female) abnormal: <10/6 or >71/42 (male/female), U/L); LDH: Lactic dehydrogenase (normal: 135–225/214 (male/female) abnormal: <135 or >225/214 (male/female), 
U/L); Sodium (normal: 136–145 low: <136 high: >145, mmol/L); Calcium ion (normal: 2.20–2.55 abnormal: <2.20 or >2.55, mmol/L); BU: Blood urea (normal: 3.6/3.1–9.5/8.8 (male/female) low: <3.6/3.1 (male/female) high: 
>9.5/8.8 (male/female), mmol/L); HCO: Bicarbonate radical (normal: 22.0–29.0 low: <22.0 high: >29.0, mmol/L); eGFR: Epidermal growth factor receptor (normal: >90 abnormal: ≤90, mL/min/1.73m2); PT: Prothrombin time 
(normal: 11.5–14.5 abnormal: <11.5 or >14.5,s); INR: International normalized ratio (normal: 0.80–1.20 abnormal: >1.20); FIB: Fibrinogen (normal: 2.00–4.00 low: <2.00 high: >4.00, g/L); D-D dimer quantification (normal:<0.5 
abnormal: ≥0.5,μg/mL FEU); IL-2R: Interleukin-2 receptor (normal: 223–710 low: <223 high: >710, U/mL); IL-6: Interleukin 6 (normal: <7.0 abnormal: ≥7.0, pg/mL); IL-8: Interleukin 8 (normal: <62 abnormal: ≥62, pg/mL); 
IL-10: Interleukin 10 (normal: <9.1 abnormal: ≥9.1, pg/mL).
Table 1: (Continued)
Table 2: Collinearity diagnostics results
Model Collinearity statistics
Tolerance VIF
Age 0.492 2.032
WBC 0.567 1.765
LC 0.523 1.911
NT-PROBNP 0.483 2.070
Hypersensitive cardiac troponin 0.540 1.851
TP 0.244 4.105
DBIL 0.617 1.621
GGT 0.826 1.211
LDH 0.169 5.903
Sodium 0.159 6.270
Calcium ion 0.026 38.389
HCO 0.037 27.243
PT 0.528 1.893
INR 0.954 1.048
FIB 0.608 1.644
D-D dimer quantification 0.513 1.948
IL-2R 0.374 2.676
IL-6 0.028 35.273
NEUT 0.444 2.252
PCT 0.045 22.313
AST 0.096 10.420
Albumin 0.319 3.139
BU 0.205 4.879
eGFR 0.236 4.234
IL-8 0.030 33.805
IL-10 0.109 9.157
WBC: White blood cell count; LC: Lymphocyte count; NT-PROBNP: Amino-terminal pro-brain natriuretic 
peptide; TP: Total protein; DBIL: Direct bilirubin; GGT: Gamma-glutamyl transpeptidase; LDH: Lactic 
dehydrogenase; HCO: Bicarbonate radical; PT: Prothrombin time; INR: International normalized ratio; 
FIB: Fibrinogen; IL-2R: Interleukin-2 receptor 2; IL-6: Interleukin 6; NEUT: Neutrophil count; 
PCT: procalcitonin; AST: Glutamic oxalacetic transaminase; BU: Blood urea;; eGFR: Epidermal growth 
factor receptor; IL-8: Interleukin 8; IL-10: Interleukin 10.
Table 3: Collinearity diagnostics after adjusting variables
Model Collinearity statistics
Tolerance VIF
Age 0.712 1.404
WBT 0.599 1.670
LC 0.542 1.845
NT-PROBNP 0.789 1.267
Hypersensitive cardiac troponin 0.620 1.614
TP 0.319 3.132
DBIL 0.689 1.450
GGT 0.921 1.086
LDH 0.356 2.808
Sodium 0.428 2.336
PT 0.549 1.823
INR 0.970 1.031
FIB 0.710 1.409
D-D dimer quantification 0.555 1.801
IL-2R 0.474 2.109
NEUT 0.467 2.140
Albumin 0.358 2.793
IL-10 0.643 1.556
WBC: White blood cell count; LC: Lymphocyte count; NT-PROBNP: Amino-terminal pro-brain natriuretic 
peptide; TP: Total protein; DBIL: Direct bilirubin; GGT: Gamma-glutamyl transpeptidase; LDH: Lactic 
dehydrogenase; PT: Prothrombin time; INR: International normalized ratio; FIB: Fibrinogen; 
IL-2R: Interleukin-receptor 2; NEUT: Neutrophil count; IL-10: Interleukin 10.
Multivariate analysis results
The variables whose p < 0.05 in a single factor 
analysis and whose missing values were filled were 
included in Cox regression analysis, the method was 
forward: LR, with inclusion criteria of 0.05 and exclusion 
criteria of 0.10. We found that lactic dehydrogenase 
(LDH), age, fibrinogen (FIB), and disease severity 
were associated with delayed clearance of viral RNA 
in patients, as shown in Table 4. Then, drew the Kaplan 
and Meier curves and performed Log Rank test, as 
shown in Figures 1-4.
Table 4: Multivariate analysis results
Variables B SE Wald df p-value HR 95.0% CI for HR
Age −0.302 0.137 4.824 1 0.028 0.739 (0.565,0.968)
Disease severity −1.111 0.172 41.540 1 0.000 0.329 (0.235,0.462)
FIB normal 19.555 2 0.000
Low −0.657 0.530 1.537 1 0.215 0.519 (0.184,1.465)
High −0.715 0.162 19.406 1 0.000 0.489 (0.356,0.672)
LDH −0.532 0.161 10.952 1 0.001 0.587 (0.428,0.805)
FIB: Fibrinogen (normal: 2.00–4.00 low: <2.00 high: >4.00, g/L); LDH: Lactic dehydrogenase.
Discussion
We found that on the whole, men were less 
likely than women to undergo negative conversion 
of SARS-CoV-2 RNA (p < 0.05), which was consist 
with some other studies to some extent [13], [14], 
[15]. However, in our study, univariate Cox regression 
showed that gender was not related factor, so we did 
not include it. By the end of observation, the median 
duration of virus in the control group was 24 days 
that in the negative conversion group was 17 days; 
the difference was statistically significant (p < 0.05). 
It is very important to study the factors related to the 
negative transformation of the virus to shorten the 
duration of the virus and eliminate the virus in the body 
as soon as possible.
In our study, multivariate Cox regression 
showed that age was a relevant factor for viral nucleic 
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acid negative transformation, and those younger than 
65 years were more likely to have negative conversion 
than those older than 65 years (HR = 0.739, p < 0.05).
Figure 2: Negative conversion curves in coronavirus disease-19 
patients according to disease severity
When the cutoff for age was set at 45 years as a related 
study did [16], we did not find this difference between 
the two age groups.
Figure 3: Negative conversion curves in coronavirus disease-19 
patients according to fibrinogen
So we set the cutoff at 65 years as another research 
did [17] and found age > 65 years was a factor 
associated with viral negative conversion. First, older 
patients have a poorer prognosis as some studies 
showed [18], [19], [20]. Then, elderly patients are prone 
to systemic complications that may affect the clearance 
of SARS-CoV-2 [21]. In addition, it is generally believed 
that with age, immune system becomes weaker. 
Therefore, the risk of infection increases and the virus 
is difficult to remove from the body [22], [23].
Figure 4: Negative conversion curves in coronavirus disease-19 
patients according to lactic dehydrogenase
We found that the clearance of SARS-CoV-2 
was associated with disease severity. It will be less 
conducive to virus removal if the illness at the time 
of admission is more serious. Ding Shi and other 
researchers have proved the same result [17]. The 
consensus view is that having severe COVID-19 
symptoms affects the prognosis. As we all know, 
the more serious the disease is, the more critical 
complications may happen, which may affect the 
clearance of the virus in the body [24], [25].
Early studies have suggested that COVID-19 
patients were easy to present with coagulopathy, 
disseminated intravascular coagulation, and other 
complications [26], [27], [28]. Based on this finding, our 
study has demonstrated that high levels of FIB were related 
to the delayed virus clearance. Although few studies have 
been consistent with our results, some researchers have 
confirmed that FIB seems to increase early in COVID-
19 patients or severe patients and may be used as a 
risk stratification marker [29], [30]. As for the mechanism 
of clotting disorder, according to relative research, the 
endothelial glycocalyx is one of the important targets in 
the pathogenesis of virus-induced coagulopathy, while it 
still remains to be clarified whether similar mechanisms 
exist in COVID-19 or not. Besides, in a severer viral 
infection, both direct virus-induced cytotoxic effect and 
indirect injury may damage the host, pro-inflammatory 
cytokines and chemokines reported in COVID-19 were 
examples [31], [32]. For coagulation disorders, the 
corresponding treatment may indirectly help the virus to 
turn negative so as to improve the prognosis.
Meta-analysis showed that the laboratory 
indicator abnormality that COVID-19 patients were more 
likely to occur was the elevated LDH level and it had 
stronger correlations with COVID-19 mortality [20], [33]. 
In other studies, patients were divided into the severe 
group with diabetes and the group without diabetes, the 
Figure 1: Negative conversion curves in coronavirus disease-19 
patients according to age
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cardiovascular disease group and the non-cardiovascular 
disease group. The results showed that the level of LDH 
in the former group was higher than that in the control 
group, which indicates the increase of LDH may be 
associated with cooccurring chronic diseases. These 
patients were more likely to suffer from multiple organ 
dysfunction syndrome [6], [34]. It has been reported 
that the cause of elevated LDH may be that the virus 
damages muscles and myocardial [35]. Increased LDH 
may cause the decrease of cytosolic pH and exacerbate 
muscle soreness [36]. Therefore, it is necessary to 
detect the LDH concentration in time and to determine 
the degree of damage to important organs in the body.
We studied the related factors from the 
perspective of virus negative conversion. It has been 
rarely studied in the previous research. In addition, 
variables with missing values greater than 20% were 
eliminated and other missing values were filled to ensure 
the stability of multi-factor analysis results. However, 
this study still has some shortcomings. Factors that may 
affect the lab indicators, such as comorbidities, were not 
included in the analysis because of the excessive lack 
of data and the causal relationship between laboratory 
findings and disease severity could not be determined.
Conclusion
Our study found that age older than 65 years, 
more severe disease; the elevated levels of LDH and 
FIB were not conducive to the negative conversion of 
SARS-CoV-2 RNA. Under the same conditions, the 
elevated group would prolong the virus clearance time. 
Therefore, in the treatment of COVID-19, attention 
should be paid to people over 65 years old and in critical 
condition and monitor these indicators, so as to control 
the inflammation and organ damage caused by viral 
infection, and help to improve the prognosis of patients.
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